



Patent claims**1. Compounds of formula 1**

in which

- R1** is phenyl,
 phenyl substituted by R3 and/or R4,
 naphthalenyl,
 naphthalenyl substituted by R5 and/or R6,
 aryl1,
 aryl1 substituted by R7 and/or R8,
 R9,
 R10 or
 R11,
- R2** is phenyl,
 phenyl substituted by R12 and/or R13,
 naphthalenyl,
 naphthalenyl substituted by R14 and/or R15,
 aryl2,
 aryl2 substituted by R16 and/or R17
 or a radical selected from



- R3** is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl,

- 83 -

aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R31)R32$, $-CH_2CH(OH)CH_2N(R31)R32$ or $-O-(CH_2)_m-N(R31)R32$ wherein

R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or wherein

R31 and R32 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

n is an integer from 0 to 4,


m is an integer from 2 to 4,

- R4 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,
- R5 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R31)R32$, $-CH_2CH(OH)CH_2N(R31)R32$ or $-O-(CH_2)_m-N(R31)R32$,
- R6 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,
- Aryl1 furanyl, thiophenyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl or dibenzofuranyl,
- R7 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzy-

- 84 -

loxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R_{31})R_{32}$, $-CH_2CH(OH)CH_2N(R_{31})R_{32}$ or $-O-(CH_2)_m-N(R_{31})R_{32}$,


- R8 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,
- R9 is unsubstituted pyrrolyl, pyrazolyl, imidazolyl, indolyl, indazolyl, benzimidazolyl or benzotriazolyl, or a radical selected from



wherein

- R91 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R_{31})R_{32}$, $-CH_2CH(OH)CH_2N(R_{31})R_{32}$ or $-O-(CH_2)_m-N(R_{31})R_{32}$,
- R92 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,
- R10 is a radical selected from

- 85 -




wherein

R101 is 1-4C-alkyl, 2,2,2-trifluoroethyl or 3,3,3-trifluoropropyl,

R102 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R11 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, $-(CH_2)_p-N(R112)R113$ or $-CH_2CH(OH)CH_2N(R112)R113$, wherein

R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or wherein

R112 and R113 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

- 86 -

- R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkyl-amino,
- R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkyl-amino,
- Aryl2 furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzo-furanyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]-dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,
- R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkyl-amino,

and the salts of these compounds with the proviso that the following compounds are excluded

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-[6-(2-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(4-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-(3-[6-[4-(Toluene-4-sulfonylamino)-phenylamino]-pyrimidin-4-yl]-phenyl)-acetamide,
 N-[4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
 4-Methyl-N-[4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
 N-[4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,

- 87 -

N-[4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(2',4'-Dimethoxy-[4,5]bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide, and
 4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide.

2. Compounds of formula 1 according to claim 1 in which

R1 is phenyl,

phenyl substituted by R3 and/or R4,

naphthalenyl or

naphthalenyl substituted by R5 and/or R6,

R2 is phenyl,

phenyl substituted by R12 and/or R13,


naphthalenyl,

naphthalenyl substituted by R14 and/or R15,

aryl2,

aryl2 substituted by R16 and/or R17

or a radical selected from



R3 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy or benzyloxy,

- 88 -

- R4 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,
- R5 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy or benzyloxy,
- R6 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,
- R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- Aryl2 furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,
- R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

and the salts of these compounds with the proviso that the following compounds are excluded

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-[6-(2-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(4-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,

- 89 -

N-[4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-(3-[6-[4-(Toluene-4-sulfonylamino)-phenylamino]-pyrimidin-4-yl]-phenyl)-acetamide,
N-[4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
4-Methyl-N-[4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
N-[4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
N-[4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide, and
N-[4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide.

3. Compounds of formula 1 according to claim 1 in which

- R1 is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3-acetylphenyl, 4-acetylphenyl, 3-cyanophenyl, 4-phenoxyphenyl or naphthalen-1-yl,
R2 is phenyl, phenyl substituted by R12 and/or R13, thiophenyl, naphthalenyl or 5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-yl,
R12 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine or 1-4C-alkoxycarbonyl,
R13 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

and the salts of these compounds with the proviso that the following compounds are excluded

4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide, and
N-[4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide.

4. Compounds of formula 1 according to claim 1 in which

- R1 is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-acetylphenyl or naphthalen-1-yl,
R2 is 2-fluorophenyl, 3-fluorophenyl, 3,4-difluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluorophenyl, 3-chloro-4-methylphenyl, 3-bromophenyl, 3-methylphenyl, 4-methylphenyl, 4-isopropylphenyl, 4-trifluoromethylphenyl, 4-methoxyphenyl, 4-cyanophenyl or 5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-yl,

and the salts of these compounds with the proviso that the following compounds are excluded


4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide and
4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide.

5. Compounds of formula 1 according to claim 1 in which

- R1 is phenyl substituted by R3 and/or R4 or naphthalenyl substituted by R5 and/or R6,

- 90 -

- R2 is phenyl,
 phenyl substituted by R12 and/or R13,
 naphthalenyl,
 naphthalenyl substituted by R14 and/or R15,
 aryl2,
 aryl2 substituted by R16 and/or R17
 or a radical selected from



- R3 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R31)R32$, $-CH_2CH(OH)CH_2N(R31)R32$ or $-O-(CH_2)_m-N(R31)R32$, wherein

R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or wherein

R31 and R32 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

n is an integer from 0 to 4,

m is an integer from 2 to 4,

- R4 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

- R5 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy,

- 91 -

1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R_{31})R_{32}$, $-CH_2CH(OH)CH_2N(R_{31})R_{32}$ or $-O-(CH_2)_m-N(R_{31})R_{32}$,

- R6 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,
- R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- Aryl2 furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,
- R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

and the salts of these compounds.

6. Compounds of formula 1 according to claim 1 in which

- R1 is phenyl substituted in para or meta position by R3 or phenyl substituted in para and meta position by R3 and R4,
- R2 is phenyl substituted by R12 and/or R13,
- R3 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-

- 92 -

4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R_{31})R_{32}$, $-CH_2CH(OH)CH_2N(R_{31})R_{32}$ or $-O-(CH_2)_m-N(R_{31})R_{32}$, wherein

R₃₁ is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R₃₂ is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or wherein

R₃₁ and R₃₂ together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

n is an integer from 1 to 4,

m is an integer from 2 to 4,

R₄ is fluorine, methyl or methoxy,

R₁₂ is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R₁₃ is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkyl-amino,

and the salts of these compounds.

7. Compounds of formula 1 according to claim 1 in which

R₁ is phenyl substituted in para or meta position by R₃,

R₂ is phenyl substituted by R₁₂ and/or R₁₃,

R₃ is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R_{31})R_{32}$, $-CH_2CH(OH)CH_2N(R_{31})R_{32}$ or $-O-(CH_2)_m-N(R_{31})R_{32}$, wherein

R₃₁ is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R₃₂ is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or wherein

R₃₁ and R₃₂ together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

n is an integer from 1 to 4,

- 93 -

m is an integer from 2 to 4.

- R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkyl-amino,

and the salts of these compounds.

8. Compounds of formula 1 according to claim 1 in which

- R1 is phenyl substituted in para position by R3 or phenyl substituted in para position by R3 and in meta position by R4,
- R2 is phenyl substituted by R12 and/or R13,
- R3 is morpholin-4-ylmethyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, 2-morpholin-4-ylethoxy, 3-morpholin-4-ylpropoxy, 4-methylpiperazin-1-ylmethyl, 4-methylpiperazin-1-ylethyl, 4-methylpiperazin-1-ylpropyl, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 1-methylpiperidin-4-ylmethoxy, 1-methylpiperidin-4-ylmethyl, 1-methylpiperidin-4-ylethyl, 1-methylpiperidin-4-ylpropyl, 2-(1-methylpiperidin-4-yl)ethoxy, 3-(1-methylpiperidin-4-yl)propoxy, pyrrolidin-1-ylpropyl, pyrrolidin-1-ylethyl, pyrrolidin-1-ylmethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethoxy, piperidin-1-ylmethyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, 2-(piperidin-1-yl)ethoxy, 3-(piperidin-1-yl)propoxy,
- R4 is fluorine, methyl or methoxy,
- R12 is fluorine, chlorine, cyano, methyl, isopropyl, trifluoromethyl or methoxy,
- R13 is fluorine or chlorine,

and the salts of these compounds.

9. Compounds of formula 1 according to claim 1 in which

- R1 is phenyl substituted in para or meta position by R3,
- R2 is phenyl substituted by R12 and/or R13,
- R3 is morpholin-4-ylmethyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, 2-morpholin-4-ylethoxy, 3-morpholin-4-ylpropoxy, 4-methylpiperazin-1-ylmethyl, 4-methylpiperazin-1-ylethyl, 4-methylpiperazin-1-ylpropyl, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 1-methylpiperidin-4-ylmethoxy, 1-methylpiperidin-4-ylmethyl, 1-methylpiperidin-4-ylethyl, 1-methylpiperidin-4-ylpropyl, 2-(1-methylpiperidin-4-yl)ethoxy, 3-(1-methylpiperidin-4-yl)propoxy, pyrrolidin-1-ylpropyl, pyrrolidin-1-ylethyl, pyrrolidin-1-ylmethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethoxy, piperidin-1-ylmethyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, 2-(piperidin-1-yl)ethoxy, 3-(piperidin-1-yl)propoxy,
- R12 is fluorine, chlorine, cyano, methyl, isopropyl, trifluoromethyl or methoxy,

- 94 -

R13 is fluorine or chlorine,
and the salts of these compounds.

10. Compounds of formula 1 according to claim 1 in which

R1 is phenyl substituted in para position by R3 or phenyl substituted in para position by R3 and in meta position by R4,

R2 is 2-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl, 2-fluoro-4-methylphenyl, 2-fluoro-4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methylphenyl, 4-methoxyphenyl or 3-chloro-4-fluorophenyl,

R3 is 2-morpholin-4-ylethoxy, 3-morpholin-4-ylpropoxy, 4-methylpiperazin-1-ylethoxy, 4-methylpiperazin-1-ylpropoxy, morpholin-4-ylmethyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, 1-methylpiperidin-4-ylmethoxy, 2-(1-methylpiperidin-4-yl)ethoxy, 4-methylpiperazin-1-ylethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethoxy or 3-pyrrolidin-1-ylpropyl,

R4 is fluorine,
and the salts of these compounds.

11. Compounds of formula 1 according to claim 1 in which

R1 is phenyl substituted in para or meta position by R3,

R2 is 2-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl, 4-methylphenyl, 4-methoxyphenyl or 3-chloro-4-fluorophenyl,

R3 is 2-morpholin-4-ylethoxy, 3-morpholin-4-ylpropoxy, 4-methylpiperazin-1-ylethoxy, 4-methylpiperazin-1-ylpropoxy, morpholin-4-ylmethyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, 1-methylpiperidin-4-ylmethoxy, 2-(1-methylpiperidin-4-yl)ethoxy, 4-methylpiperazin-1-ylethyl, 3-pyrrolidin-1-ylpropoxy, 2-pyrrolidin-1-ylethoxy or 3-pyrrolidin-1-ylpropyl,


and the salts of these compounds.

12. Compounds of formula 1 according to claim 1 in which

R1 is aryl1,
aryl1 substituted by R7 and/or R8,
R9 or
R10,


R2 is phenyl,
phenyl substituted by R12 and/or R13,
naphthalenyl,
naphthalenyl substituted by R14 and/or R15,
aryl2,
aryl2 substituted by R16 and/or R17
or a radical selected from

- 95 -



- Aryl1 furanyl, thiophenyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl or dibenzofuranyl,
- R7 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R31)R32$, $-CH_2CH(OH)CH_2N(R31)R32$ or $-O-(CH_2)_m-N(R31)R32$, wherein
- R31 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and
- R32 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl or wherein
- R31 and R32 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,
- n is an integer from 0 to 4,
- m is an integer from 2 to 4,
- R8 is halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,
- R9 is unsubstituted pyrrolyl, pyrazolyl, imidazolyl, indolyl, indazolyl, benzimidazolyl or benztriazolyl, or a radical selected from

- 96 -




wherein

R91 is hydroxyl, halogen, cyano, carboxyl, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, phenoxy, benzyloxy, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkoxy, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkoxy, $-(CH_2)_n-N(R31)R32$, $-CH_2CH(OH)CH_2N(R31)R32$ or $-O-(CH_2)_m-N(R31)R32$,

R92 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R10 is a radical selected from



wherein

R101 is 1-4C-alkyl, 2,2,2-trifluoroethyl or 3,3,3-trifluoropropyl,

- 97 -

- R102 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,
- R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- Aryl2 furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]-dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,
- R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

and the salts of these compounds with the proviso that the following compounds are excluded

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide, and
 4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide.

13. Compounds of formula 1 according to claim 1 in which

- 98 -

- R1 is pyrid-3-yl, pyrid-4-yl, 2-methyl-2,3-dihydrobenzofuran-5-yl, benzo[1,3]dioxol-5-yl, 1-methyl-1H-pyrrol-3-yl, 4-methyl-thiophen-2-yl, 1-methyl-1H-pyrrol-2-yl, 1H-indol-5-yl, 1-methyl-1H-indol-3-yl, 1-methyl-1H-indol-5-yl, dibenzofuran-4-yl or 3,5-dimethyl-isoxazol-4-yl,
- R2 is phenyl substituted by R12 and/or R13 or naphthalenyl,
- R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkyl-amino,

and the salts of these compounds with the proviso that the following compounds are excluded

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide, and
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide.

14. Compounds of formula 1 according to claim 1 in which

- R1 is 2-methyl-2,3-dihydrobenzofuran-5-yl, benzo[1,3]dioxol-5-yl, 1-methyl-1H-pyrrol-3-yl, 4-methyl-thiophen-2-yl, 1-methyl-1H-pyrrol-2-yl, 1H-indol-5-yl, 1-methyl-1H-indol-3-yl or 1-methyl-1H-indol-5-yl,
- R2 is phenyl substituted by R12 and/or R13 or naphthalenyl,
- R12 is fluorine, chlorine, cyano, methyl, trifluoromethyl or methoxy,
- R13 is fluorine, chlorine or methoxy,

and the salts of these compounds with the proviso that the compound

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide is excluded.

15. Compounds of formula 1 according to claim 1 in which

- R1 is 2-methyl-2,3-dihydrobenzofuran-5-yl, 1-methyl-1H-pyrrol-3-yl or 4-methylthiophen-2-yl, and
R2 is 2,6-difluorophenyl,
or
R1 is 1H-indol-5-yl, and
R2 is 2,6-difluorophenyl, 2,4-difluorophenyl, 2-fluoro-4-methylphenyl, 2-fluorophenyl or 3-fluorophenyl,
or
R1 is 1-methyl-1H-indol-5-yl or 1-methyl-1H-indol-3-yl, and
R2 is 2,6-difluorophenyl, 2-fluorophenyl or 4-methoxyphenyl,
or
R1 is 1-methyl-1H-indol-5-yl, and
R2 is 2-fluoro-4-methylphenyl,
and the salts of these compounds.

- 99 -

16. Compounds of formula 1 according to claim 1 in which

either

R1 is 2-methyl-2,3-dihydrobenzofuran-5-yl, 1-methyl-1H-pyrrol-3-yl or 4-methylthiophen-2-yl, and

R2 is 2,6-difluorophenyl,

or

R1 is 1H-indol-5-yl, and

R2 is 2,6-difluorophenyl, 2,4-difluorophenyl, 2-fluorophenyl or 3-fluorophenyl,

or

R1 is 1-methyl-1H-indol-5-yl or 1-methyl-1H-indol-3-yl, and

R2 is 2,6-difluorophenyl, 2-fluorophenyl or 4-methoxyphenyl,

and the salts of these compounds.

17. Compounds of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl,

phenyl substituted by R12 and/or R13,


naphthalenyl,

naphthalenyl substituted by R14 and/or R15,

aryl²,


aryl² substituted by R16 and/or R17

or a radical selected from



R11 is a radical selected from

- 100 -



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, $-(CH_2)_p-N(R112)R113$ or $-CH_2CH(OH)CH_2N(R112)R113$, wherein

R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or wherein

R112 and R113 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R14 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R15 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

Aryl2 furanyl, thiophenyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothienophenyl, 2,3-dihydrobenzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]-

- 101 -

dioxinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, phthalazinyl, indanyl, indolyl or indazolyl,

R16 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R17 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkyl-amino,


and the salts of these compounds.

18. Compounds of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl substituted by R12 and/or R13,

R11 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, $-(CH_2)_p-N(R112)R113$ or $-CH_2CH(OH)CH_2N(R112)R113$, wherein

R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or wherein

R112 and R113 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

- 102 -


- R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,
- R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkyl-amino,
- and the salts of these compounds.

19. Compounds of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl substituted by R12 and/or R13,

R11 is a radical selected from



wherein

R111 is 1-(1-4C-alkyl)-pyrrolidin-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-pyrrolidin-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-piperid-4-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-2-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-3-yl-1-4C-alkyl, 1-(1-4C-alkyl)-azepan-4-yl-1-4C-alkyl, $-(CH_2)_p-N(R112)R113$ or $-CH_2CH_2(OH)CH_2N(R112)R113$, wherein

R112 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, and

R113 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, or wherein

R112 and R113 together and with inclusion of the nitrogen atom to which they are bonded form a pyrrolidin-, piperidin-, 4-hydroxy-piperidin-, piperazin-, 4-(1-4C-alkyl)piperazin-, [1,4]diazepan-, 4-(1-4C-alkyl)-[1,4]diazepan-, morpholin-, thiomorpholin- or an azepan-ring,

p is an integer from 1 to 4,

R114 is hydrogen, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy or 1-4C-alkoxy completely or predominantly substituted by fluorine, amino or mono- or di-1-4C-alkylamino,

R12 is hydroxyl, halogen, cyano, nitro, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkylamino,

R13 is hydroxyl, halogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino or mono- or di-1-4C-alkyl-amino,

and the salts of these compounds.


- 103 -

20. Compounds of formula 1 according to claim 1 in which

R1 is R11,

R2 is phenyl substituted by R12 and/or R13,

R11 is a radical selected from



wherein

R111 is pyrrolidin-1-ylethyl, pyrrolidin-1-ylpropyl, piperidin-1-ylethyl, piperidin-1-ylpropyl, azepan-1-ylethyl, azepan-1-ylpropyl, (4-methyl-piperazin-1-yl)ethyl, (4-methyl-piperazin-1-yl)propyl, morpholin-4-ylethyl, morpholin-4-ylpropyl, (1-methyl-piperidin-4-yl)propyl, (1-methyl-piperidin-4-yl)ethyl, (1-methyl-piperidin-4-yl)methyl, dimethylaminoethyl, dimethylaminopropyl, dimethylaminobutyl, diethylaminoethyl, diethylaminopropyl or diethylaminobutyl,

R114 is hydrogen or fluorine,

R12 is fluorine, chlorine, cyano, methyl, isopropyl, trifluoromethyl or methoxy,

R13 is fluorine or chlorine,


and the salts of these compounds.

21. Compounds of formula 1 according to claim 1 in which

R1 is R11,

R2 is 2-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl, 4-methylphenyl, 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 2-fluoro-4-methylphenyl, or 3-chloro-4-fluorophenyl,

R11 represents the following radical



wherein

R111 is pyrrolidin-1-ylethyl, pyrrolidin-1-ylpropyl, (4-methyl-piperazin-1-yl)ethyl, (4-methyl-piperazin-1-yl)propyl, (1-methyl-piperidin-4-yl)ethyl, (1-methyl-piperidin-4-yl)methyl, dimethylaminoethyl, dimethylaminopropyl, diethylaminopropyl or diethylaminobutyl,

and the salts of these compounds.

22. Compounds according to claim 1 for use in the treatment of diseases.

- 104 -

23. Pharmaceutical compositions containing one or more compounds according to claim 1 together with the usual pharmaceutical auxiliaries and/or excipients.
24. Use of compounds according to claim 1 for the production of pharmaceutical compositions for the treatment of acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock. The compounds according to the invention are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjogren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis.
25. A method for treating acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjogren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis in a patient comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.
26. A compound selected from
4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

- 105 -

N-[4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-[6-(2-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(4-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-(3-[6-[4-(Toluene-4-sulfonylamino)-phenylamino]-pyrimidin-4-yl]-phenyl)-acetamide,
 N-[4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
 4-Methyl-N-[4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
 N-[4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
 N-[4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 or a salt thereof for use in the treatment of diseases.

27. Pharmaceutical composition containing one or more compounds selected from
 4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-[6-(2-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(4-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 N-(3-[6-[4-(Toluene-4-sulfonylamino)-phenylamino]-pyrimidin-4-yl]-phenyl)-acetamide,
 N-[4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,

- 106 -

4-Methyl-N-[4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
N-[4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
N-[4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
or a salt thereof together with the usual pharmaceutical auxiliaries and/or excipients.

28. Use of a compound selected from

4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-[6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-[6-(2-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-[6-(4-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-(3-[6-[4-(Toluene-4-sulfonylamino)-phenylamino]-pyrimidin-4-yl]-phenyl)-acetamide,
N-[4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
4-Methyl-N-[4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
N-[4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
N-[4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

- 107 -

4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 or a salt thereof for the production of pharmaceutical compositions for the treatment of acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock. The compounds according to the invention are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjogren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis.

29. A method for treating acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjogren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from 4-Methyl-N-[4-(6-naphthalen-2-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
 N-[4-(6-(Bis-trifluoromethyl-phenyl)-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
 4-Methyl-N-[4-(6-phenyl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,

- 108 -

4-Methyl-N-[4-(6-naphthalen-1-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-[6-(2-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-[6-(4-Benzoyloxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-[6-(3,4-Dimethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-[6-(4-Hydroxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-(3-[6-[4-(Toluene-4-sulfonylamino)-phenylamino]-pyrimidin-4-yl]-phenyl)-acetamide,
N-[4-[6-(2-Methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-[6-(3-nitro-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
4-Methyl-N-[4-[6-(4-trifluoromethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
N-[4-[6-(4-Cyano-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-[6-(4-morpholin-4-yl-phenyl)-pyrimidin-4-ylamino]-phenyl]-benzenesulfonamide,
N-[4-[6-(3-Amino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-[6-(3-Dimethylamino-phenyl)-pyrimidin-4-ylamino]-phenyl]-4-methyl-benzenesulfonamide,
N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide
or a salt thereof.

30. A compound selected from

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide, and
4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
or a salt thereof for use in the treatment of diseases.

31. Pharmaceutical compositions containing one or more compounds selected from N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,

4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
or a salt thereof together with the usual pharmaceutical auxiliaries and/or excipients.

32. Use of compounds selected from

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
or a salt thereof for the production of pharmaceutical compositions for the treatment of acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock. The compounds according to the invention are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjogren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis.

33. A method for treating acute or chronic rejection of organ or tissue allo- or xenografts, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, hypertension, heart failure,

- 110 -

chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjogren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis In a patient comprising administering to said patient a therapeutically effective amount of a compound selected from

N-[4-(6-Benzo[1,3]dioxol-5-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-4-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(2',4'-Dimethoxy-[4,5']bipyrimidinyl-6-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-pyridin-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Benzofuran-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
4-Methyl-N-[4-(6-thiophen-3-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide,
N-[4-(6-Benzo[b]thiophen-2-yl-pyrimidin-4-ylamino)-phenyl]-4-methyl-benzenesulfonamide, and
4-Methyl-N-[4-(6-quinolin-8-yl-pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide,
or a salt thereof.